Taiwan Stock Exchange · Healthcare
Standard Chem & Pharm stock from India: price, numbers and tax
Standard Chem & Pharm (1720) is not currently available to trade on Paasa; this guide covers the price, the numbers and the Indian tax treatment.
By Paasa · Updated
Standard Chem & Pharm at a glance
- Price
- NT$56.10-NT$0.20 (0.36%)
- Market cap
- NT$11.03B
- Day range
- NT$55.90 – NT$56.10
- P/E
- 10.43
- Dividend yield
- 3.57%
- Volume
- 73.75K
- 1 month
- +0.00%
- 6 months
- -3.72%
- YTD
- +4.76%
- 1 year
- +8.83%
- 5 years
- +64.13%
Standard Chem & Pharm statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | NT$7.0B | NT$6.8B | NT$6.2B | NT$5.9B | NT$4.6B |
| Gross profit | NT$2.9B | NT$3.0B | NT$2.7B | NT$2.5B | NT$2.1B |
| Operating income | NT$1.4B | NT$1.4B | NT$1.3B | NT$1.4B | NT$1.0B |
| Net income | NT$927.7M | NT$880.5M | NT$834.9M | NT$1.2B | NT$706.7M |
| Earnings per share | NT$5.19 | NT$4.94 | NT$4.67 | NT$6.46 | NT$3.96 |
| EBITDA | NT$1.8B | NT$2.1B | NT$1.6B | NT$1.7B | NT$1.2B |
| Total assets | NT$11.8B | NT$11.2B | NT$11.2B | NT$11.0B | NT$10.1B |
| Total debt | NT$1.1B | NT$921.2M | NT$1.3B | NT$2.2B | NT$2.0B |
| Cash and short-term investments | NT$2.4B | NT$1.8B | NT$2.3B | NT$2.6B | NT$3.0B |
| Shareholders' equity | NT$6.1B | NT$5.9B | NT$5.3B | NT$4.8B | NT$4.3B |
| Operating cash flow | NT$1.9B | NT$1.7B | NT$1.3B | NT$1.2B | NT$827.0M |
| Free cash flow | NT$1.4B | NT$1.1B | NT$710.8M | NT$30.3M | NT$609.1M |
| Capital expenditure | −NT$489.3M | −NT$599.6M | −NT$625.7M | −NT$1.2B | −NT$217.9M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in TWD; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| AP Biosciences | 6945.TWO | $143.00 | $13.87B |
| Vizionfocus | 4771.TW | NT$213.50 | NT$12.53B |
| Foresee Pharmaceuticals | 6576.TWO | $79.10 | $12.46B |
| TaiDoc Technology | 4736.TW | NT$130.00 | NT$12.40B |
| TCM Biotech International | 4169.TWO | $171.00 | $11.36B |
| PharmaEngine | 4162.TWO | $55.30 | $7.95B |
| Medeon Biodesign | 6499.TWO | $79.10 | $7.67B |
| Bioteque | 4107.TWO | $110.50 | $7.66B |
Peers as grouped by the data provider. This is not an investment recommendation.
Why invest in Standard Chem & Pharm from India
What Standard Chem & Pharm does
Standard Chem & Pharm Co. Ltd. (SCP) is a Taiwanese enterprise specializing in the development, manufacturing, and commercialization of a broad spectrum of pharmaceutical products, nutritional supplements, and Active Pharmaceutical Ingredients (APIs). The company's diverse offerings include medications targeting various therapeutic areas, such as the circulatory, digestive, and respiratory systems. Standard Chem & Pharm operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
What tax do I pay in India when I sell Standard Chem & Pharm shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the TWD/INR rate on the day you bought and the day you sold, so the currency move is part of the gain.